Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
24-hour IOP-lowering Effect of Brimonidine 0.1%
NCT00457795Phase 4Completed
- Sponsor
- Allergan
- Start
- Dec 2006
- Primary completion
- Feb 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of brimonidine in open-angle glaucoma (OAG), ocular hypertension, sponsored by Allergan. Started Dec 2006; status: completed.
02
Drugs
brimonidine
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on NCT00457795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00457795.